FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:1899-1901 November 5, 2009 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kenter, G. G. PubMed Citation

Cancer immunoprevention has become synonymous with the vaccines that have been approved for the prevention of infection with highly transmissible strains of human papillomavirus (HPV) that establish chronic infection and cause cervical and other cancers.¹ Although many cancers may have a viral origin,² only a small number of viruses have been implicated as causes of human cancer. Cancer having a viral origin provides an opportunity to develop virus-specific vaccines that lower infection rates and consequently lower the incidence of cancer; this is what the HPV vaccine is expected to do for cervical cancer and what the hepatitis B vaccine has . . . [Full Text of this Article]

Source Information

From the Departments of Immunology (O.J.F.) and Obstetrics and Gynecology (R.P.E.), University of Pittsburgh School of Medicine, Pittsburgh.

This article has been cited by other articles:

• (2009). Therapeutic HPV Vaccination for Preventing Progression of Vulvar Intraepithelial Neoplasia. JWatch Women's Health 2009: 1-1 [Full Text]